The performance of Blackstone Inc. (BX) in the investment market has been dynamic with several stakeholders altering their positions. Washington Trust Bank, Resona Asset Management Co. Ltd., Soltis Investment Advisors LLC, EFG Asset Management North America Corp., and Key Financial Inc made new acquisitions of BX shares. In contrast, AlphaQuest LLC, American Assets Capital Advisers LLC, SouthState Corp, and Freestone Capital Holdings LLC reduced their stake. Amid this, a significant move comes as the firm secures $700 million funding from Merck for cancer therapy development. However, it also reported sales below analyst estimates in Q3 earnings and is exiting a $1.8 billion senior housing investment. BX shares experienced a downward trend, raising concerns over its future direction. Evaluations of BX's valuation followed its recent share price decline. A standout transaction is the deal signed by Merck with Blackstone for a $700M deal for cancer drug development. As it's set to increase its dividends, some maintain a neutral recommendation for BX. Jonathan Gray of Blackstone warns investors about underestimating AI’s disruptive potential while its Q3 earnings reveal robust growth in AUM and upped distributable earnings.
Blackstone BX News Analytics from Thu, 24 Jul 2025 07:00:00 GMT to Sat, 08 Nov 2025 14:26:55 GMT -
Rating -1
- Innovation 3
- Information 7
- Rumor -3
